Is Stryker (SYK) Halal? 2026 AAOIFI Analysis
We use primary sources, dated financial data, and a documented review process. Read our editorial policy.
AAOIFI screening result
SYK: Compliant
Stryker's medical-technology business passes the activity screen, and all current financial ratios remain below AAOIFI thresholds.
Based on Halalytic's AAOIFI 30/30/5 screen dated July 11, 2026, Stryker (SYK) is compliant. This is a dated screening snapshot, not a permanent fatwa: company filings, market capitalization, and scholarly analysis can change the result.
What does Stryker do?
Stryker develops medical and surgical equipment, neurotechnology, orthopaedic products, and related services. Products intended to improve patient care are generally permissible. Investors should still distinguish the Shariah screen from broader questions about product safety, healthcare pricing, and commercial practices.
Primary company source: Stryker — About.
SYK AAOIFI screening breakdown
| Screen | Result | AAOIFI limit | Status |
|---|---|---|---|
| Interest-bearing debt / market cap | 12.05% | Below 30% | Pass |
| Cash and interest-bearing securities / market cap | 2.42% | Below 30% | Pass |
| Non-permissible income / revenue | 0.00% | Below 5% | Pass |
Business activity: Pass · Sector: Healthcare · Industry: Medical devices. The income screen uses reported interest income as a proxy when available.
Why the result can change
Stryker has substantial headroom in the current debt and cash screens, while the interest-income proxy is effectively zero in the screening data. Acquisitions are central to medical-device industry growth, so acquisition financing is the balance-sheet item most likely to change this profile.
- Debt issued for acquisitions
- Changes in cash and interest-bearing investments
- Any new business line outside the current medical-technology focus
Investment questions beyond halal status
Passing a Shariah screen does not mean a stock is undervalued, financially safe, or suitable for a particular portfolio. A non-compliant verdict is also not a prediction that the share price will fall.
- How durable is procedure and hospital demand?
- Are acquisition prices creating integration or impairment risk?
- How exposed is Stryker to recalls, litigation, and regulatory approvals?